Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Anemia
Interventions: Sodium ferric gluconate, ferrous sulfate, standard of care; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 32
States / cities: Bakersfield, California • Chula Vista, California • Long Beach, California + 29 more

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate Complex in Sucrose Injection, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Vasoconstriction, Vasodilation
Interventions: Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside; Other · Drug
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disease, Myelodysplastic Syndromes, Aplastic Anemia
Interventions: Hepatic biomagnetic susceptibility measurement; Device
Lead sponsor: Columbia University; Other
Eligibility: 5 Years to 80 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions: SPD602; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York + 1 more

Conditions: Iron Overload
Interventions: Not listed
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 2 Years to 25 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: sodium nitroprusside, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Glen Oaks, New York + 1 more

Conditions: Iron-deficiency Anemia
Interventions: Clinical supports; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Transfusional Iron Overload, Beta-Thalassemia
Interventions: SPD602; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Feeding Behavior
Interventions: Education; Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 1 Week to 12 Months
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anemia of Prematurity, Very Low Birth Weight Infant
Interventions: 2mg/kg/day Iron Sulfate, 6 mg/kg/day Iron Sulfate; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 1 Day to 6 Months
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Nonheme Iron Absorption
Interventions: My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7; Behavioral
Lead sponsor: USDA Grand Forks Human Nutrition Research Center; Federal
Eligibility: 21 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Grand Forks, North Dakota

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Iron Overload
Interventions: GE Optima/Discovery® MRI data of the liver; Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 10 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Blood Loss Anemia, Fracture
Interventions: Iron-Dextran Complex Injection [InFed], Saline Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
Interventions: Sodium ferric gluconate,; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 29
States / cities: Bakersfield, California • Glendale, California • Los Angeles, California + 26 more

Conditions: Chronic Iron Overload Due to Transfusion-dependant Anemias
Interventions: Deferasirox dispersible tablet, Defearisox film-coated tablet; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years and older
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Orange, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Anemia, Iron Deficiency, Delivery Complication
Interventions: Ferrous sulfate, Iron dextran; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Iron Deficiency
Interventions: Iron sucrose; Drug
Lead sponsor: The Guthrie Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Sayre, Pennsylvania

Conditions: Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Interventions: Ferric derisomaltose, Placebo (normal saline); Drug
Lead sponsor: Duke University; Other
Eligibility: 65 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Iron Deficiency Anemia of Pregnancy
Interventions: Ferrous sulfate 325mg, Ferumoxytol; Dietary Supplement · Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Thalassemia, Iron Overload, Hemochromatosis
Interventions: Nifedipine, Phlebotomy, Urinalysis, Echocardiogram, Electrocardiogram; Drug · Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: THALASSEMIA MAJOR
Interventions: Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI; Other
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 12 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Oakland, California

Conditions: Bleeding Disorders, Iron, Platelet, Bleeding
Interventions: IV Iron (standard of care); Drug
Lead sponsor: Nicoletta C Machin; Other
Eligibility: 15 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients

Role of Acetylcholine in Blood Flow Regulation in Healthy Adults: Effects of Age and Exercise Training

High-Tc Susceptometer to Monitor Transfusional Iron Overload

Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

Changes in Pituitary Iron and Volume With Deferasirox

A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia

EHR-based Patient Identification and Panel Management of Patients With Iron Deficiency Anemia

Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Evaluation of Feeding Practices in Latin American Infants at a Medical Home in Austin, Texas

Iron Supplementation and Intestinal Health

Iron Bioavailability From MyPyramid Menus

Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Non-invasive Quantification of Liver Iron With MRI

Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma

DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)

Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

The Safety of a High-Dose, Rapid Infusion of Iron Sucrose

IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

Intravenous Infusions of Ferumoxytol Compared to Oral Ferrous Sulfate for the Treatment of Anemia in Pregnancy

Oral Nifedipine to Treat Iron Overload

Reproductive Capacity and Iron Burden in Thalassemia

Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders